Meeting
2024 ASCO Breakthrough
Non-invasive minimal residual disease detection of liver cancer using circulating tumor DNA features and α-fetoprotein: A prospective study.
Authors
Yinyin Chang
Clinical Laboratories, Shenyou Bio, Zhengzhou, China
Yinyin Chang , Qingqi Ren , Shiyong Li , Liangliang Zhang , Yumin Feng , Guanghui Long , Mao Mao
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B
Track
Thoracic Cancers,Breast Cancer,Gynecologic Cancer,Head and Neck Cancer,Hematologic Malignancies,Genetics/Genomics/Multiomics,Healthtech Innovations,Models of Care and Care Delivery,Viral-Mediated Malignancies,Other Malignancies or Topics
Sub Track
Omics for precision medicine
Citation
J Clin Oncol 42, 2024 (suppl 23; abstr 229)
DOI
10.1200/JCO.2024.42.23_suppl.229
Abstract #
229
Poster Bd #
H6
Abstract Disclosures
Similar Posters
Poster
2019 Gastrointestinal Cancers Symposium
Clinicopathological features and outcomes of fibrolamellar hepatocellular carcinoma.
First Author: Sakti Chakrabarti
Poster
2023 ASCO Annual Meeting
Association of positive ctDNA-based minimal residual disease assays during surveillance and undiagnosed concomitant radiographic recurrences in colorectal cancer (CRC): Results from the MD Anderson INTERCEPT program.
First Author: Arvind Dasari
Poster
2022 ASCO Annual Meeting
Utilization of cell-free DNA fragmentomics in minimal residual disease detection for non-small cell lung cancer.
First Author: Rong Yin
Poster
2021 ASCO Annual Meeting
Minimal residual disease by circulating tumor DNA analysis for colorectal cancer patients receiving radical surgery: An initial report from CIRCULATE-Japan.
First Author: Hiroki Yukami